Related Experiment Video

Updated: Apr 19, 2026

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine
10:05

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine

Published on: July 7, 2016

9.0K

[Effect of pharmacotherapy of chronic heart failure (CHF) on the parameters of hemogram]

V V Kutovoĭ, V K Kazimirko, L N Ivanitskaia

    Likars'Ka Sprava
    |December 17, 2014
    PubMed

    Insights

    Combined drug therapy for chronic heart failure improved blood counts, with the most significant effects seen with ACE inhibitors, ARB-II, beta-blockers, and diuretics. Higher hemoglobin correlated with better exercise capacity.

    Area of Science:

    • Cardiology
    • Hematology

    Context:

    • Chronic heart failure (CHF) management involves complex therapeutic regimens.
    • Erythropoiesis and hemoglobin levels can be affected in CHF patients.
    • Optimizing drug combinations is crucial for improving patient outcomes.

    Purpose:

    • To evaluate the impact of different combined drug therapies on hematological parameters in chronic heart failure patients.
    • To identify the most effective drug combination for improving erythrocyte and hemoglobin levels.
    • To explore correlations between hematological changes and clinical markers of heart failure.

    Summary:

    • Combined drug therapy, particularly involving ACE inhibitors, ARB-II, beta-blockers, and diuretics, increased erythrocytes, hemoglobin, and hematocrit in CHF patients.
    • A direct positive correlation was observed between hemoglobin levels and 6-minute walk test distance.
    • Hemoglobin levels showed an inverse correlation with left ventricular end-diastolic volume and heart failure functional class, while red blood cell count inversely correlated with functional class.

    Impact:

    • Findings suggest that specific combination therapies can positively influence hematological status in CHF.
    • Improved hematological parameters may correlate with enhanced functional capacity and reduced disease severity in heart failure.
    • This research provides insights into optimizing pharmacotherapy for CHF by considering hematological effects.

    More Related Videos

    Cutoff Value of Phase Angle by Bioelectrical Impedance Analysis at Admission as a Prognostic Factor in Patients with Acute Heart Failure05:16

    Cutoff Value of Phase Angle by Bioelectrical Impedance Analysis at Admission as a Prognostic Factor in Patients with Acute Heart Failure

    Published on: June 10, 2025

    798
    Induction and Phenotyping of Acute Right Heart Failure in a Large Animal Model of Chronic Thromboembolic Pulmonary Hypertension07:41

    Induction and Phenotyping of Acute Right Heart Failure in a Large Animal Model of Chronic Thromboembolic Pulmonary Hypertension

    Published on: March 17, 2022

    3.5K

    Related Concept Videos

    Heart Failure V: Medical Management01:30

    Heart Failure V: Medical Management

    Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
    594
    Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

    Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

    Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
    365
    Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

    Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

    The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
    1.5K
    Heart Failure Drugs: β-Blockers01:22

    Heart Failure Drugs: β-Blockers

    β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
    1.2K
    Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

    Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

    In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
    266
    Heart Failure VI: Adjunct Therapies01:22

    Heart Failure VI: Adjunct Therapies

    Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
    614